P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE studyAndrés Yarur, Brian Bressler, M Bassel et al.|Journal of Crohn s and Colitis|2019Cited by 8
P546 Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim resultsBrian Bressler, Dirk Demuth, A. Greenup et al.|Journal of Crohn s and Colitis|2018Cited by 4
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVEGerassimos J. Mantzaris, Andrés Yarur, Shu Wang et al.|Journal of Crohn s and Colitis|2020Cited by 4